About ADMA Biologics
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ADMA
- Previous Close: $4.78
- 50 Day Moving Average: $5.08
- 200 Day Moving Average: $5.67
- 52-Week Range: $4.15 - $8.85
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.92
- P/E Growth: 0.00
- Market Cap: $61.60M
- Outstanding Shares: 12,886,000
- Beta: 2.79
- Net Margins: -198.45%
- Return on Equity: -6,405.90%
- Return on Assets: -76.16%
Companies Related to ADMA Biologics:
- Debt-to-Equity Ratio: -92.07%
- Current Ratio: 2.76%
- Quick Ratio: 2.25%
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?
2 analysts have issued 12-month target prices for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they expect ADMA Biologics' share price to reach $13.00 in the next year.
When will ADMA Biologics announce their earnings?
ADMA Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.
Who owns ADMA Biologics stock?
ADMA Biologics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (8.64%), Perceptive Advisors LLC (5.60%), FMR LLC (3.28%) and Franklin Resources Inc. (2.79%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen.
Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?
ADMA Biologics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen.
How do I buy ADMA Biologics stock?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ADMA Biologics stock cost?
One share of ADMA Biologics stock can currently be purchased for approximately $4.78.